Biosimilars

Optimise the opportunity and understand the competitor environment

Biologics, whose active substance is derived from a living organism, have enabled healthcare to make significant therapeutic advances across a whole raft of therapy areas since their introduction in the 1970s. However, these medicines come at a price, reflecting the complexities involved in developing and manufacturing products derived from living cells. Annual treatment costs in the US can range from US$25,000 to US$200,000.

Biosimilars medicines, (the approved follow-on products to innovator biologics) which have come off-patent, present a significant opportunity to introduce cutting-edge therapies to the treatment landscape for many diseases, while also addressing the cost-effectiveness demands now being made on global healthcare systems.

But biosimilars aren’t like standard generic medicines and cannot be easily replicated. The extent to which they will win market share will depend on a range of factors including regulatory behaviour, physician and patient attitudes, trust and understanding, as well as manufacturing capabilities. Research Partnership has been working with both biologic and biosimilar manufacturers and understands the market factors at play.

We can help you with:

  • Opportunity and demand assessment

  • Understanding the global and local market opportunity

  • Segmenting the market

  • Product and portfolio development

  • Brand positioning, launch and beyond

Biosimilars resources:

Needle-1

Article

Read more about biosimilars breaking policy and perceptual barriers.

Find out more

Biosimilars article

Article

Learn more about developing biosimilars in Asia.


Find out more

Biosimilar case study

Case study

Find out how we helped our client to evaluate early biosimilar user experience.

Learn more